Armed with two pivotal study hits Astellas Pharma, Inc.’s zolbetuximab is headed for the regulators later this year, and now comes the next wave of projects that also hit Claudin18.2. Investor focus recently fell on one of these, Elevation Oncology, Inc.’s SYSA1801, and the 3 June data presentation at the American Society of Clinical Oncology (ASCO) annual meeting appeared to back up some of the enthusiasm.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?